Skip to main
LQDA
LQDA logo

LQDA Stock Forecast & Price Target

LQDA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 0%
Sell 13%
Strong Sell 0%

Bulls say

Liquidia Corp demonstrates a positive outlook due to its expected cash-flow positivity and profitability arriving sooner than anticipated, aided by disciplined selling, general, and administrative expenses (SG&A), improved gross margins, and an efficient specialty-pharmacy model that enhances operational leverage. The company has reported strong early launch metrics for its product YUTREPIA, highlighting sustained referral momentum, growing prescriber adoption, and broad payer access, indicating a healthy market presence. Additionally, the management's innovative "white-glove" access model has achieved a notable 75% pull-through rate, reflecting effective patient conversion and adherence, which could further bolster revenue growth.

Bears say

Liquidia Corp faces significant investor concerns regarding the potential approval of sotatercept, which could reduce the demand for its existing prostacyclin-based therapies, thereby impacting revenue projections for its product YUTREPIA. The company may struggle to achieve peak commercial revenue estimates due to factors such as market size, penetration rates, and pricing, which could adversely affect its financial outlook. Furthermore, Liquidia is operating in a highly competitive environment, and any failures in clinical trials or negative safety signals could lead to substantial decreases in asset value and increased volatility of the stock.

LQDA has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Liquidia Technologies Inc (LQDA) Forecast

Analysts have given LQDA a Buy based on their latest research and market trends.

According to 8 analysts, LQDA has a Buy consensus rating as of Oct 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Liquidia Technologies Inc (LQDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.